All In Biotech

Drug Trial Radar · NCT07686120

A Phase IIIb Study to Investigate the Effect of Baxdrostat in Chinese Participants With Uncontrolled Hypertension.

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Baxdrostat on Ambulatory Blood Pressure in Chinese Participants With Uncontrolled Hypertension on Two or More Antihypertensive Medications Without Diuretics

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 286 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

286

Planned (sponsor's estimate)

Start

Sep 17, 2026

Primary completion

Feb 9, 2028

Study completion Feb 9, 2028

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Tigermed Consulting Co., Ltd
First posted
Jul 7, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase IIIb, multicentre, randomised, double-blind, placebo-controlled, parallel group study to evaluate the effect of baxdrostat 2mg versus placebo, administered QD orally, on the reduction of ambulatory 24-hour average SBP in participants with uHTN. Consenting participants will be screened within 4 weeks and will subsequently enter a 4-week run-in period with placebo. Thereafter, participants will be randomised in a 1:1 ratio to receive one of the following 2 treatments QD, during a 12-week double-blind treatment period: baxdrostat 2mg Placebo The randomisation will be stratified by mean ambulatory SBP at baseline (\<140 mmHg, ≥140 mmHg) and the number of background antihypertensive medication classes (2, ≥3) at baseline. During the 12-week double-blind treatment period, participants should remain on their background antihypertensive medication. Doses of background medications should not be changed during this period unless participants experience SBP \< 100 mmHg with symptoms of hypotension. Rescue therapy is permitted if the SBP or DBP exceeds 170 or 105 mmHg, respectively. The choice of rescue therapy is based on the Investigator's best clinical judgement; however, the use of potassium-sparing diuretics and MRAs are prohibited.After completing the 12 weeks double-blind treatment period participants will complete a 2-week safety follow-up period. The total duration of study participation will be of approximately 22 weeks.

Conditions

  • Uncontrolled Hypertension

Interventions

  • baxdrostat 2mgDrug

    baxdrostat 2mg tablet administered orally, once daily (QD).

  • Placebo 2mgDrug

    Placebo 2mg tablet administered orally, once daily (QD).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in ambulatory 24-hour average Systolic blood pressure(SBP) at Week 12Time frame: Week12

Locations

51 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Beijing, China · Recruiting

  • Research Site

    Beijing, China · Not yet recruiting

  • Research Site

    Beijing, China · Not yet recruiting

  • Research Site

    Beijing, China · Not yet recruiting

  • Research Site

    Bengbu, China · Not yet recruiting

  • Research Site

    Changchun, China · Not yet recruiting

  • Research Site

    Changsha, China · Not yet recruiting

  • Research Site

    Chengdu, China · Not yet recruiting

  • Research Site

    Chengdu, China · Not yet recruiting

  • Research Site

    Chongqing, China · Not yet recruiting

  • Research Site

    Foshan, China · Not yet recruiting

  • Research Site

    Fuzhou, China · Not yet recruiting

  • Research Site

    Fuzhou, China · Not yet recruiting

  • Research Site

    Guangzhou, China · Not yet recruiting

  • Research Site

    Guangzhou, China · Not yet recruiting

  • Research Site

    Guangzhou, China · Not yet recruiting

  • Research Site

    Haikou, China · Not yet recruiting

  • Research Site

    Hangzhou, China · Not yet recruiting

  • Research Site

    Jinan, China · Not yet recruiting

  • Research Site

    Jinan, China · Not yet recruiting

  • Research Site

    Kunming, China · Not yet recruiting

  • Research Site

    Lanzhou, China · Not yet recruiting

  • Research Site

    Lu'an, China · Not yet recruiting

  • Research Site

    Nanchang, China · Not yet recruiting

  • Research Site

    Nanjing, China · Not yet recruiting

  • Research Site

    Nanjing, China · Not yet recruiting

  • Research Site

    Nanjing, China · Not yet recruiting

  • Research Site

    Nanning, China · Not yet recruiting

  • Research Site

    Ningbo, China · Not yet recruiting

  • Research Site

    Qingdao, China · Not yet recruiting

  • Research Site

    Shanghai, China · Not yet recruiting

  • Research Site

    Shanghai, China · Not yet recruiting

  • Research Site

    Shanghai, China · Not yet recruiting

  • Research Site

    Shanghai, China · Not yet recruiting

  • Research Site

    Shanghai, China · Not yet recruiting

  • Research Site

    Shantou, China · Not yet recruiting

  • Research Site

    Shenyang, China · Not yet recruiting

  • Research Site

    Shenzhen, China · Not yet recruiting

  • Research Site

    Shijiazhuang, China · Not yet recruiting

  • Research Site

    Suzhou, China · Not yet recruiting

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.